(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes
Clinicians at the University Hospital Erlangen show how a new laser-based imaging technique termed MSOT can detect inflammation more accurately than current non-invasive diagnostic procedures and thereby help reduce the burden to patients MUNICH, 30-Mar-2017 — /EuropaWire/ — Ulcerative colitis … Read the full press release
Posted in France, Germany, Healthcare, Italy, Netherlands, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Christian Wiest, Clinicians, Crohn's disease, Crohn's disease patients, detection of melanoma metastasis, diagnosis, diagnostic imaging, Dr. Ferdinand Knieling, hemoglobin values, IBD, inflammation, inflammatory bowel disease, intestinal mucosa, invasive endoscopy procedure, iThera Medical, laser light, laser-based imaging technique, medical device, medical imaging, MSOT, MSOT technology, Multspectral Optoacoustic Tomography, new diagnostic imaging modality, New England Journal of Medicine, non-invasive assessment, optoacoustic, optoacoustic imaging, photoacoustic, Prof. Dr. Maximilian Waldner, sentinel lymph nodes, suspicious breast lesions, Ulcerative colitis, ultrasound, University Hospital Erlangen
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?